Seeking Alpha

Protalix (PLX +5.5%) signs an agreement with Pfizer (PFE) in which the latter will conduct and...

Protalix (PLX +5.5%) signs an agreement with Pfizer (PFE) in which the latter will conduct and sponsor new trials for Protalix's Elelyso treatment for Gaucher disease, which stops cells and organs from working properly. Protalix will be eligible to receive milestone payments of up $8.3M; the company will continue to conduct existing trials of Elelyso. (PR)
Comments (3)
  • Jay Adler Comment
    , contributor
    Comments (49) | Send Message
     
    Pfizer is a terrific pipeline drug conglomerate in the drug industry. They have the cash for continued substantial investment for future growth.
    6 Dec 2012, 10:34 AM Reply Like
  • Walkingwounded
    , contributor
    Comments (244) | Send Message
     
    Still waiting for Brazil to OK the drug.
    6 Dec 2012, 01:14 PM Reply Like
  • popster76
    , contributor
    Comments (213) | Send Message
     
    This is a continuation of the PFE strategy to make the search for new medicines more efficient by investing in innovative research with smaller biotechs and rare diseases in dire need of new therapies. The in-house R&D continues to be slimmed down into centers of excellence around the world, with focus on the really big areas of greatest need including cancer, Alzheimer's, vaccines, etc. The spin-offs of the Nutrition and Animal Health businesses provided the cash to fuel this strategy being directed by Ian Read and his direct reports. This is the reason I remain long in PFE and committed to the future of this company's stock.
    6 Dec 2012, 04:23 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector